BMY.RT

Bristol-Myers Squibb Company Contingent Value Rights
BMY.RT

Overview Fund Trends Analyst Outlook Journalist POV
Delisted

BMY.RT was delisted on the 31st of December, 2020.

Back to rankings

12 hedge funds and large institutions have $5.25M invested in Bristol-Myers Squibb Company Contingent Value Rights in 2021 Q1 according to their latest regulatory filings, with 2 funds opening new positions, 1 increasing their positions, 1 reducing their positions, and 527 closing their positions.

New
Increased
Maintained
Reduced
Closed

more repeat investments, than reductions

Existing positions increased: | Existing positions reduced:

less funds holding

Funds holding: →

less capital invested

Capital invested by funds: $ → $

less first-time investments, than exits

New positions opened: | Existing positions closed:

100% less funds holding in top 10

Funds holding in top 10: 5 → 0 (-5)

Holders
12
Holders Change
Holders Change %
% of All Funds
Holding in Top 10
–
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
Increased
Reduced
Closed
Calls
–
Puts
–
Net Calls
Net Calls Change

Top Buyers

1
+$2.15M
2
+$146K

Top Sellers

1
-$47.7M
2
-$20.6M
3
-$17.1M
4
FCM
Farallon Capital Management
California
-$14.8M
5
BFS
Bard Financial Services
Connecticut
-$13.7M
Name Holding Trade Value Shares
Change 		Change in
Stake
1
$2.53M
2
$2.15M
3
$410K
4
$146K
5
$7K
6
$2K
7
–
8
–
9
–
10
–
11
–
12
–
13
–
14
–
15
–
16
–
17
–
18
–
19
–
20
–
21
–
22
–
23
–
24
–
25
–
1
2 3 4 5